MarketInOut Stock Screener Log In | Sign Up

Ascendis Pharma A/S

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Ascendis Pharma A/S stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization16,534 mln
Float64.91 mln
Earnings Date11/11/2026

EPS

13.05
Robust

P / E

19.25
Moderately valued

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

2.7
Highly suspicious

1-Year Forecast

303.89
Attractive

Relative Strength

93 / 100
Top performer

Business Description

Founded in Denmark in 2006, Ascendis Pharma is a drug development company built around its proprietary TransCon technology, which is designed to improve how medicines work in the body. The company currently sells two approved treatments ? one for children with growth hormone deficiency and another for adults with a rare condition affecting calcium regulation. Beyond these products, Ascendis is advancing additional treatments for rare hormonal disorders and exploring new therapies in cancer care.

Key Fundamentals

EPS13.05
P/E19.25
ROE277
RPS18.33
ROIC8.39
ROA48.50
Interest Cover0.51
EBITDA, mln394
EV / EBITDA41.74
EV / EBIT44.04
Revenue, mln1,221
EV / Revenue13.47

Quote Details

Last 251.27
Change -1.73 (-0.68%)
Open 253.50
Volume 386,641
Turnover 97,151,288
Average Volume 687,503

Financial Ratios

Pre-Tax Profit Margin10
Leverage Ratio1.59
Current Ratio2.99
Price / Book9.83
Price / Tangible Book9.86
Price / Cash Flow41.06
Price / Free Cash Flow42.26
Debt / Equity0.31
Price / Sales12.88
PEG Ratio0.90

Financial Strength

Altman Z-Score10.22
Piotroski F-Score 7 / 9
Beneish M-Score2.7
Price to Graham Number2.86
1-Year Target Price303.89
Short Ratio3.27
Short % of Float5.63

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.25% 84 / 100   
1 Month 10.54% 92 / 100   
2 Months -0.85% 53 / 100   
6 Months 13.73% 86 / 100   
1 Year 22.15% 81 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog